Showing results (1371-1380 of 1,523) with videos related to

Sort By:
Pageof 153
The Lancet. Respiratory Medicine|June 2, 2020
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trialYi-Long Wu, Ying Cheng, Jianying Zhou, et al.
JAMA Oncology|September 2, 2021
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical TrialLeora Horn, Ziping Wang, Gang Wu, et al.
Lung Cancer (Amsterdam, Netherlands)|May 18, 2019
Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancerKeunchil Park, Jaafar Bennouna, Michael Boyer, et al.
Cancer Cell|February 5, 2010
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLCAlexa B Turke, Kreshnik Zejnullahu, Yi-Long Wu, et al.
Lung Cancer (Amsterdam, Netherlands)|March 31, 2026
Adjuvant immunotherapy may have no impact on survival in patients who received neoadjuvant immunotherapy for stage II-IIIB non-small cell lung cancerJun-Tao Lin, Xue-Ning Yang, Xiang-Meng Li, et al.
Oncotarget|August 18, 2016
Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterationsNa-Na Lou, Xu-Chao Zhang, Hua-Jun Chen, et al.
Lung Cancer (Amsterdam, Netherlands)|August 27, 2024
Tumor immune microenvironment of NSCLC with EGFR exon 20 insertions may predict efficacy of first-line ICI-combined regimenKe-Jun Liu, Hong-Rui Li, Quan-Quan Tan, et al.
Science Progress|March 19, 2025
The combination of immune checkpoint inhibitor and chemotherapy may be efficacious for advanced non-small cell lung cancer with near-loop insertions of EGFR exon 20: A retrospective analysisKe-Jun Liu, Hong-Rui Li, Quan-Quan Tan, et al.
Cancer|November 27, 2019
Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancerVassiliki A Papadimitrakopoulou, Ji-Youn Han, Myung-Ju Ahn, et al.
Thoracic Cancer|July 7, 2018
Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancerJin Kang, Hua-Jun Chen, Xu-Chao Zhang, et al.
Pageof 153